Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
NERV 
Minerva Neurosciences Inc (NERV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/25/2026: NERV (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4
1 Year Target Price $4
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 26.92M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 1 | Beta -0.42 | 52 Weeks Range 1.15 - 6.69 | Updated Date 12/13/2025 |
52 Weeks Range 1.15 - 6.69 | Updated Date 12/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.85 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -25.82% | Return on Equity (TTM) -675.09% |
Valuation
Trailing PE - | Forward PE 11.21 | Enterprise Value -520497 | Price to Sales(TTM) 1.87 |
Enterprise Value -520497 | Price to Sales(TTM) 1.87 | ||
Enterprise Value to Revenue 0.03 | Enterprise Value to EBITDA 2.6 | Shares Outstanding 6993406 | Shares Floating 5437023 |
Shares Outstanding 6993406 | Shares Floating 5437023 | ||
Percent Insiders 22.25 | Percent Institutions 28.26 |
Upturn AI SWOT
Minerva Neurosciences Inc
Company Overview
History and Background
Minerva Neurosciences Inc. was founded in 2003 with a focus on developing treatments for central nervous system (CNS) disorders. Initially known as Transmolecular, Inc., it underwent a name change to Minerva Neurosciences in 2014 following its merger with Minerva Biotechnologies and a subsequent reverse merger with Sonnet BioTherapeutics. A significant milestone was its initial public offering (IPO) in 2014. The company has been dedicated to advancing its pipeline through clinical trials for conditions like schizophrenia and insomnia.
Core Business Areas
- Neuroscience Drug Development: Minerva Neurosciences is primarily engaged in the discovery and development of novel therapies for significant unmet medical needs in the central nervous system (CNS) space. Their focus is on developing small molecule drugs targeting specific neurotransmitter systems and pathways involved in neurological and psychiatric disorders.
Leadership and Structure
Minerva Neurosciences Inc. is led by a management team with experience in drug development and the pharmaceutical industry. The organizational structure is typical for a biotechnology company, with dedicated teams for research and development, clinical operations, regulatory affairs, and commercial strategy. Specific leadership roles, such as CEO, CFO, and Chief Medical Officer, are detailed in their public filings and on their corporate website.
Top Products and Market Share
Key Offerings
- MIN-101 (Roluperidone): MIN-101 is Minerva's lead drug candidate, a selective serotonin-dopamine modulator designed for the treatment of schizophrenia. It has undergone Phase II and Phase III clinical trials. While specific market share figures are not yet available as the drug is not yet approved or marketed, its target market is the global schizophrenia therapeutics market, which is highly competitive. Competitors include companies developing antipsychotics like AbbVie (Vraylar), Johnson & Johnson (Invega), and Otsuka Pharmaceutical (Abilify).
- MIN-202 (Agalta): MIN-202 is a selective serotonin 5-HT2A receptor antagonist and alpha-7 nicotinic acetylcholine receptor partial agonist, investigated for the treatment of insomnia and potentially other CNS disorders. It has also progressed through clinical trials. Similar to MIN-101, market share data is not applicable as it is not yet commercialized. The insomnia treatment market is competitive, with established drugs and therapies available.
Market Dynamics
Industry Overview
The neuroscience drug development industry is characterized by high research and development costs, long development timelines, and significant regulatory hurdles. However, it also presents a substantial market opportunity due to the prevalence of neurological and psychiatric disorders and the ongoing need for more effective and safer treatments. The market is driven by scientific advancements, an aging global population, and increasing awareness of mental health.
Positioning
Minerva Neurosciences is positioned as a clinical-stage biopharmaceutical company focused on developing differentiated therapies for CNS disorders. Its competitive advantage lies in its proprietary drug candidates with novel mechanisms of action aimed at addressing unmet needs in schizophrenia and insomnia. However, as a smaller company, it faces significant competition from larger, more established pharmaceutical companies with extensive resources and existing market presence.
Total Addressable Market (TAM)
The TAM for schizophrenia therapeutics is estimated to be in the tens of billions of dollars globally, with significant unmet needs for patients who do not respond well to current treatments or experience severe side effects. The insomnia market is also substantial. Minerva Neurosciences' positioning is to capture a segment of this TAM with its pipeline candidates, assuming successful clinical development and regulatory approval.
Upturn SWOT Analysis
Strengths
- Proprietary drug candidates (MIN-101, MIN-202) with novel mechanisms of action.
- Experienced management team in drug development.
- Focus on significant unmet medical needs in CNS disorders.
- Progress in clinical trials for key drug candidates.
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies.
- Reliance on the success of a few key drug candidates.
- Clinical trial failures can significantly impact the company.
- Lack of a marketed product to generate revenue.
Opportunities
- Growing demand for effective treatments for CNS disorders.
- Potential for strategic partnerships or acquisitions by larger companies.
- Advancements in understanding brain chemistry and disease pathways.
- Expansion into other CNS indications for its drug candidates.
Threats
- Intense competition in the CNS therapeutics market.
- Regulatory risks associated with drug approval processes.
- Potential for clinical trial failures or adverse events.
- Changes in healthcare policies and reimbursement landscapes.
- Patent expirations of competitor drugs leading to market shifts.
Competitors and Market Share
Key Competitors
- Johnson & Johnson (JNJ)
- AbbVie Inc. (ABBV)
- Otsuka Pharmaceutical Co., Ltd. (OTSUKY.PK)
- Pfizer Inc. (PFE)
- Sunovion Pharmaceuticals Inc. (a subsidiary of Sumitomo Pharma)
Competitive Landscape
Minerva Neurosciences faces a highly competitive landscape dominated by large pharmaceutical companies with established portfolios and significant R&D budgets. Minerva's advantage lies in its focus on potentially novel mechanisms for schizophrenia and insomnia, addressing limitations of current therapies. However, its disadvantages include limited resources, smaller scale of operations, and the inherent risks of clinical development compared to established players.
Growth Trajectory and Initiatives
Historical Growth: Minerva Neurosciences has experienced growth in its pipeline progression, moving drug candidates through different phases of clinical trials. This growth is marked by scientific milestones rather than financial revenue growth, as is typical for pre-commercialization biotechs.
Future Projections: Future growth projections are contingent on the successful clinical development, regulatory approval, and commercialization of its lead drug candidates, MIN-101 and MIN-202. Analyst estimates would focus on the potential market penetration and peak sales if these drugs are approved.
Recent Initiatives: Recent initiatives likely involve advancing ongoing clinical trials, seeking regulatory feedback, and potentially exploring strategic partnerships or collaborations to fund further development and commercialization efforts.
Summary
Minerva Neurosciences Inc. is a clinical-stage biopharmaceutical company with a focused pipeline on CNS disorders, particularly schizophrenia and insomnia. Its strengths lie in its novel drug candidates and experienced team, while weaknesses include limited financial resources and reliance on trial success. The company has opportunities in a growing market but faces significant threats from competition and regulatory hurdles. Its future hinges on the successful progression and approval of its lead drug candidates, MIN-101 and MIN-202.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Minerva Neurosciences Inc. SEC Filings (10-K, 10-Q)
- Company Investor Relations Website
- Industry Market Research Reports (General)
- Financial News Outlets
Disclaimers:
This JSON output is generated based on publicly available information and should not be considered as financial advice. Stock market investments are subject to risks, and investors should conduct their own due diligence before making any investment decisions. Market share data for pre-commercial companies is indicative and subject to change upon commercialization. Competitor lists and market share percentages are estimations based on general industry knowledge and may not be exhaustive or precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Minerva Neurosciences Inc
Exchange NASDAQ | Headquaters Burlington, MA, United States | ||
IPO Launch date 2014-07-01 | Executive Chairman & CEO Dr. Remy Luthringer Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | |
Full time employees 8 | |||
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of negative symptoms in patients with schizophrenia. The company also has exclusive rights to develop and commercialize MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.